Back to Search Start Over

Δ42PD1-TLR4 Augments γδ-T Cell Activation of the Transitional Memory Subset of CD4 + T Cells.

Authors :
Mo Y
Cheung AKL
Liu Y
Liu L
Chen Z
Source :
IScience [iScience] 2020 Sep 28; Vol. 23 (10), pp. 101620. Date of Electronic Publication: 2020 Sep 28 (Print Publication: 2020).
Publication Year :
2020

Abstract

TLR ligands can contribute to T cell immune responses by indirectly stimulating antigen presentation and cytokines and directly serving as co-stimulatory signals. We have previously reported that the human endogenous surface protein, Δ42PD1, is expressed primarily on (Vγ9)Vδ2 cells and can interact with TLR4. Since Vδ2 cells possess antigen presentation capacity, we sought to further characterize if the Δ42PD1-TLR4 interaction has a role in stimulating T cell responses. In this study, we found that stimulation of Vδ2 cells not only upregulated Δ42PD1 expression but also increased MHC class II molecules necessary for the antigen presentation. In a mixed leukocyte reaction assay, upregulation of Δ42PD1 on Vδ2 cells elevated subsequent T cell proliferation. Furthermore, the interaction between Δ42PD1-TLR4 augments Vδ2 cell stimulation of autologous CMV pp65-or TT-specific CD4 <superscript>+</superscript> T cell proliferation and IFN-γ responses, which was specifically and significantly reduced by blocking the Δ42PD1-TLR4 interaction. Furthermore, confocal microscopy analysis confirmed the interaction between Δ42PD1 <superscript>+</superscript> HLA-DR <superscript>+</superscript> Vδ2 cells and TLR4 <superscript>+</superscript> CD4 T cells. Interestingly, the subset of CD4 <superscript>+</superscript> T cells expressing TLR4 appears to be PD-1 <superscript>+</superscript> CD45RO <superscript>+</superscript> CD45RA <superscript>+</superscript> transitional memory T cells and responded to Δ42PD1 <superscript>+</superscript> HLA-DR <superscript>+</superscript> Vδ2 cells. Overall, this study demonstrated an important biological role of Δ42PD1 protein exhibited by Vδ2 antigen-presenting cells in augmenting T cell activation through TLR4, which may serve as an additional co-stimulatory signal.<br />Competing Interests: The antibodies against Δ42PD1 is described in the US patent no. 10,047,137B2 (A.K.L.C. and Z.C.).<br /> (© 2020 The Authors.)

Details

Language :
English
ISSN :
2589-0042
Volume :
23
Issue :
10
Database :
MEDLINE
Journal :
IScience
Publication Type :
Academic Journal
Accession number :
33089108
Full Text :
https://doi.org/10.1016/j.isci.2020.101620